Affordable Access

Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.

Authors
  • Skapek, S X
  • VanDellen, A F
  • McMahon, D P
  • Postels, D G
  • Griffith, O W
  • Bigner, D D
  • Friedman, H S
Type
Published Article
Journal
Cancer chemotherapy and pharmacology
Publication Date
Jan 01, 1991
Volume
28
Issue
1
Pages
15–21
Identifiers
PMID: 2040029
Source
Medline
License
Unknown

Abstract

Melphalan-induced toxicity in nude mice following pretreatment with a regimen of L-buthionine sulfoximine (BSO), previously shown to enhance the activity of this alkylating agent against rhabdomyosarcoma and glioma xenografts, was examined. Mice were pretreated with i.p. BSO (2.5 mmol/kg x 7 doses at 12-h intervals plus concomitant availability of a 20-mM solution in the drinking water) or vehicle prior to a single i.p. injection of melphalan (35.65 mg/m2). As compared with control animals who received no BSO pretreatment, mice pretreated with BSO lost weight prior to therapy with melphalan (6.9% weight loss vs 0.3% weight gain; P less than 0.005) and showed a greater mean nadir weight loss after melphalan (3.8% vs. 2.1%; P = 0.049). Treatment with melphalan was associated with histologic evidence of reversible gastrointestinal toxicity, reversible myelosuppression, and histologic evidence of acute renal tubular necrosis, with no differences being observed between mice that had been pretreated with BSO and those that had been pretreated with vehicle. No evidence of cardiac, hepatic, or skeletal muscle toxicity was found in melphalan-treated animals. These results suggest that treatment of nude mice with melphalan following BSO-mediated depletion of glutathione does not result in enhanced organ toxicity despite an increase in the antineoplastic activity of this alkylating agent.

Report this publication

Statistics

Seen <100 times